{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:59:56Z","timestamp":1790006396501,"version":"4.0.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01032-9","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:01:57Z","timestamp":1790002917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Spain, Greece, and Portugal"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-1563","authenticated-orcid":false,"given":"Raquel","family":"Yahyaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argirios","family":"Dinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francina","family":"Munell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Pedro","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela A.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5654-7791","authenticated-orcid":false,"given":"David","family":"G\u00f3mez-Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel A.","family":"Kroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios I.","family":"Zafeiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"1032_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8:52.","journal-title":"Nat Rev Dis Primers"},{"key":"1032_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","volume":"1860","author":"RN Singh","year":"2017","unstructured":"Singh RN, Howell MD, Ottesen EW, Singh NN. Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech. 2017;1860:299\u2013315.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"1032_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2008.03.031","volume":"133","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Lotti F, Dittmar K, et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell. 2008;133:585\u2013600.","journal-title":"Cell"},{"key":"1032_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28:208\u201315.","journal-title":"Neuromuscul Disord"},{"key":"1032_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genom Hum Genet. 2020;21:231\u201361. https:\/\/doi.org\/10.1146\/annurev-genom-102319-103602.","journal-title":"Annu Rev Genom Hum Genet"},{"key":"1032_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IE Verhaart","year":"2017","unstructured":"Verhaart IE, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12:1\u201315.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1032_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03071-7","volume":"19","author":"MG Cattinari","year":"2024","unstructured":"Cattinari MG, de Lemus M, Tizzano E. RegistrAME: the Spanish self-reported patient registry of spinal muscular atrophy. Orphanet J Rare Dis. 2024;19(1):76. https:\/\/doi.org\/10.1186\/s13023-024-03071-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1032_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JND-190466","volume":"7","author":"K Kekou","year":"2020","unstructured":"Kekou K, Svingou M, Sofocleous C, et al. Evaluation of genotypes and epidemiology of spinal muscular atrophy in Greece: a nationwide study spanning 24 years. J Neuromuscul Dis. 2020;7(3):247\u201356. https:\/\/doi.org\/10.3233\/JND-190466.","journal-title":"J Neuromuscul Dis"},{"issue":"7-8","key":"1032_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/08830738241256154","volume":"39","author":"R Machado","year":"2024","unstructured":"Machado R, Costa C, Fineza I, Ribeiro JA. Prevalence and classification of pediatric neuromuscular disorders in the central region of Portugal. J Child Neurol. 2024;39(7\u20138):233\u201340. https:\/\/doi.org\/10.1177\/08830738241256154.","journal-title":"J Child Neurol"},{"key":"1032_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100346","volume":"2","author":"H Chaytow","year":"2021","unstructured":"Chaytow H, Faller KME, Huang YT, Gillingwater TH. Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med. 2021;2:100346.","journal-title":"Cell Rep Med"},{"key":"1032_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"1032_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1756285618754459","volume-title":"Nusinersen for spinal muscular atrophy","author":"CD Wurster","year":"2018","unstructured":"Wurster CD, Ludolph AC. Nusinersen for spinal muscular atrophy. London: SAGE Publications; 2018."},{"key":"1032_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/dmcn.15286","volume":"65","author":"T Dangouloff","year":"2023","unstructured":"Dangouloff T, Hiligsmann M, Deconinck N, et al. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Dev Med Child Neurol. 2023;65:67\u201377.","journal-title":"Dev Med Child Neurol"},{"key":"1032_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","volume":"178","author":"O Schwartz","year":"2024","unstructured":"Schwartz O, Vill K, Pfaffenlehner M, et al. Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial. JAMA Pediatr. 2024;178:540\u20137.","journal-title":"JAMA Pediatr"},{"key":"1032_CR15","unstructured":"SMA NBS Alliance. Status map. SMA NBS Alliance, 2025. https:\/\/www.sma-screening-alliance.org\/map. Accessed 20 Nov 2025."},{"key":"1032_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1177\/22143602241288095","volume":"11","author":"Vr\u0161\u010daj E, Dangouloff T, Osredkar D, Servais L, Group SNWS","year":"2024","unstructured":"Vr\u0161\u010daj E, Dangouloff T, Osredkar D, Servais L, Group SNWS. Newborn screening programs for spinal muscular atrophy worldwide in 2023. J Neuromuscul Dis. 2024;11:1180\u20139.","journal-title":"J Neuromuscul Dis"},{"key":"1032_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijns11010007","volume":"11","author":"A Berzal-Serrano","year":"2025","unstructured":"Berzal-Serrano A, Garc\u00eda-Boh\u00f3rquez B, Aller E, et al. Outcomes of a pilot newborn screening program for spinal muscular atrophy in the Valencian Community. Int J Neonatal Screen. 2025;11:7. https:\/\/doi.org\/10.3390\/ijns11010007.","journal-title":"Int J Neonatal Screen"},{"issue":"3","key":"1032_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpede.2025.503775","volume":"102","author":"ML Couce","year":"2025","unstructured":"Couce ML, Cernada M, Boix H, et al. Current situation and new steps in newborn screening in Spain. Anales de Pediatr\u00eda (English Edition). 2025;102(3):503775. https:\/\/doi.org\/10.1016\/j.anpede.2025.503775.","journal-title":"Anales de Pediatr\u00eda (English Edition)"},{"key":"1032_CR19","unstructured":"\u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf \u03a5\u03b3\u03b5\u03af\u03b1\u03c2 [Ministry of Health]. \u03a3\u03c4\u03bf \u03a4\u03b1\u03bc\u03b5\u03af\u03bf \u0391\u03bd\u03ac\u03ba\u03b1\u03bc\u03c8\u03b7\u03c2 \u03b7 \u03b4\u03b9\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b1 \u03c0\u03c1\u03bf\u03bb\u03b7\u03c0\u03c4\u03b9\u03ba\u03ce\u03bd \u03b5\u03bb\u03ad\u03b3\u03c7\u03c9\u03bd \u03b3\u03b9\u03b1 \u03c3\u03bf\u03b2\u03b1\u03c1\u03ac \u03b3\u03b5\u03bd\u03b5\u03c4\u03b9\u03ba\u03ac \u03bd\u03bf\u03c3\u03ae\u03bc\u03b1\u03c4\u03b1 [The Recovery Fund will carry out preventive checks for serious genetic diseases] [Website in Greek]. \u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf \u03a5\u03b3\u03b5\u03af\u03b1\u03c2, December 18, 2024. https:\/\/www.moh.gov.gr\/articles\/ministry\/grafeio-typoy\/press-releases\/12993-sto-tameio-anakampshs-h-dienergeia-prolhptikwn-elegxwn-gia-sobara-genetika-noshmata. Accessed 28 Jan 2026."},{"key":"1032_CR20","doi-asserted-by":"publisher","DOI":"10.2174\/1871530323666230914122955","author":"H Fonseca","year":"2024","unstructured":"Fonseca H, Ribeiro D, Guimar\u00e3es F, et al. Pilot study on newborn screening for spinal muscular atrophy. Endocr Metab Immune Disord Drug Targets. 2024. https:\/\/doi.org\/10.2174\/1871530323666230914122955.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"1032_CR21","unstructured":"Federaci\u00f3n asem. Federaci\u00f3n ASEM valora la ampliaci\u00f3n del cribado neonatal estatal a 21 patolog\u00edas y reclama avanzar en equidad y cobertura [The ASEM Federation welcomes the expansion of state-run newborn screening to 21 pathologies and calls for progress in equity and coverage] [Website in Spanish]. Federaci\u00f3n asem, May 8, 2026. https:\/\/www.asem-esp.org\/noticias\/federacion-asem-valora-la-ampliacion-del-cribado-neonatal-estatal-a-21-patologias-y-reclama-avanzar-en-equidad-y-cobertura\/. Accessed 14 July 2026."},{"issue":"274\u201380","key":"1032_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.07.033","volume":"227","author":"A Jalali","year":"2020","unstructured":"Jalali A, Rothwell E, Botkin JR, Anderson RA, Butterfield RJ, Nelson RE. Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy. J Pediatr. 2020;227(274\u201380):274\u201380.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2020.07.033.","journal-title":"J Pediatr"},{"key":"1032_CR23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","volume":"92","author":"ST Shih","year":"2021","unstructured":"Shih ST, Farrar MA, Wiley V, Chambers G. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry. 2021;92:1296\u2013304.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1032_CR24","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","volume":"25","author":"R Velikanova","year":"2022","unstructured":"Velikanova R, van der Schans S, Bischof M, van Olden RW, Postma M, Boersma C. Cost-effectiveness of newborn screening for spinal muscular atrophy in The Netherlands. Value Health. 2022;25:1696\u2013704.","journal-title":"Value Health"},{"key":"1032_CR25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","volume":"12","author":"D Weidlich","year":"2023","unstructured":"Weidlich D, Servais L, Kausar I, Howells R, Bischof M. Cost-effectiveness of newborn screening for spinal muscular atrophy in England. Neurol Ther. 2023;12:1205\u201320.","journal-title":"Neurol Ther"},{"key":"1032_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.nmd.2023.11.013","volume":"34","author":"T Dangouloff","year":"2024","unstructured":"Dangouloff T, Thokala P, Stevenson MD, et al. Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium. Neuromuscul Disord. 2024;34:61\u20137.","journal-title":"Neuromuscul Disord"},{"key":"1032_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/13696998.2024.2439734","volume":"28","author":"A Hata","year":"2025","unstructured":"Hata A, Uda A, Tanaka S, et al. Cost\u2013utility analysis of newborn screening for spinal muscular atrophy in Japan. J Med Econ. 2025;28:44\u201353.","journal-title":"J Med Econ"},{"key":"1032_CR28","doi-asserted-by":"publisher","first-page":"S238","DOI":"10.1016\/j.jval.2020.04.805","volume":"23","author":"R Arjunji","year":"2020","unstructured":"Arjunji R, Zhou J, Patel A, et al. PMU30 cost-effectiveness analysis of newborn screening for spinal muscular atrophy (SMA) in the United States. Value Health. 2020;23:S238.","journal-title":"Value Health"},{"key":"1032_CR29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40261-024-01386-8","volume":"44","author":"G Ghetti","year":"2024","unstructured":"Ghetti G, Mennini FS, Marcellusi A, Bischof M, Pistillo GM, Pane M. Cost-effectiveness analysis of newborn screening for spinal muscular atrophy in Italy. Clin Drug Investig. 2024;44:687\u2013701.","journal-title":"Clin Drug Investig"},{"key":"1032_CR30","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40120-025-00744-8","volume":"14","author":"IR Woodcock","year":"2025","unstructured":"Woodcock IR, Kariyawasam DS, Kava MP, et al. Cost-effectiveness of newborn screening for spinal muscular atrophy in Australian hospitals. Neurol Ther. 2025;14:1007\u201322.","journal-title":"Neurol Ther"},{"issue":"1","key":"1032_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03927-6","volume":"20","author":"A Pace","year":"2025","unstructured":"Pace A, Roda W, Poon C, et al. A cost\u2013utility analysis of newborn screening for spinal muscular atrophy in Canada. Orphanet J Rare Dis. 2025;20(1):428. https:\/\/doi.org\/10.1186\/s13023-025-03927-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1032_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03697-1","volume":"20","author":"CH Wang","year":"2025","unstructured":"Wang CH, Hsu TR, Liu MY, et al. Newborn screening facilitates early theranostics and improved spinal muscular atrophy outcome: five-year real-world evidence from Taiwan. Orphanet J Rare Dis. 2025;20(1):197. https:\/\/doi.org\/10.1186\/s13023-025-03697-1.","journal-title":"Orphanet J Rare Dis"},{"key":"1032_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamapediatrics.2024.0489","volume":"178","author":"M Oskoui","year":"2024","unstructured":"Oskoui M, Dangouloff T, Servais L. Universal newborn screening for spinal muscular atrophy. JAMA Pediatr. 2024;178:520\u20131.","journal-title":"JAMA Pediatr"},{"key":"1032_CR34","unstructured":"Instituto Nacional de Estad\u00edstica [National Statistics Institute]. Resultados nacionales: serie 2020\u20132070. Poblaci\u00f3n y fen\u00f3menos demogr\u00e1ficos. Nacimientos de madre residente en Espa\u00f1a, por sexo, generaci\u00f3n de la madre y a\u00f1o [National results for series 2020\u20132070. Population and demographic phenomena. Births of a mother residing in Spain, by sex, mother\u2019s generation and year]. [Website in Spanish]. IN\u0112, 2026. https:\/\/www.ine.es\/jaxi\/Tabla.htm?tpx=68648&L=0. Accessed 4 Feb 2026."},{"key":"1032_CR35","unstructured":"\u0395\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03b7 \u0394\u03b7\u03bc\u03bf\u03ba\u03c1\u03b1\u03c4\u03b9\u03b1 \u0395\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03b7 \u03a3\u03c4\u03b1\u03c4\u03b9\u03c3\u03c4\u03b9\u03ba\u03b7 \u0391\u03c1\u03c7\u03b7 [Hellenic Republic Hellenic Statistical Authority]. \u03a3\u03c4\u03bf\u03b9\u03c7\u03b5\u03b9\u03b1 \u03a6\u03c5\u03c3\u03b9\u03ba\u03b7\u03c3 \u039a\u03b9\u03bd\u03b7\u03c3\u03b7\u03c3 \u03a0\u03bb\u03b7\u03b8\u03c5\u03c3\u03bc\u03bf\u03c5: 2022 [Physical population movement data: 2022] [Website in Greek]. ELSTAT, 26 October 2023. https:\/\/www.statistics.gr\/documents\/20181\/3a2748aa-9f4c-a4fa-76b1-2c14348eaa19. Accessed 4 Feb 2026."},{"key":"1032_CR36","unstructured":"Instituto Nacional de Estat\u00edstica\u2014Statistics Portugal. Press releases. https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_pesquisa&frm_accao=PESQUISAR&frm_show_page_num=1&frm_modo_pesquisa=PESQUISA_SIMPLES&frm_texto=nascimentos&frm_modo_texto=MODO_TEXTO_ALL&frm_data_ini=&frm_data_fim=&frm_tema=QUALQUER_TEMA&frm_area=o_ine_area_Destaques. Accessed 4 Feb 2026."},{"key":"1032_CR37","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7:1601484.","journal-title":"J Mark Access Health Policy"},{"issue":"12","key":"1032_CR38","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/sj.ejhg.5201288","volume":"12","author":"S Ogino","year":"2004","unstructured":"Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12(12):1015\u201323.","journal-title":"Eur J Hum Genet"},{"key":"1032_CR39","unstructured":"Ministerio de Sanidad, Servicos Sociales e Igualdad [Ministry of Health, Social Services and Equality]. Informe de Posicionamiento Terap\u00e9utico de nusinersen (Spinraza\u00ae) en atrofia muscular espinal [Therapeutic Positioning Report of nusinersen (Spinraza\u00ae) in Spinal Muscular Atrophy]. [Website in Spanish]. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios, March 2, 2018. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-nusinersen-Spinraza-atrofia-muscular-espinal.pdf?x42382. Accessed 18 June 2026."},{"key":"1032_CR40","unstructured":"Ministerio de Sanidad, Servicos Sociales e Igualdad [Ministry of Health, Social Services and Equality]. Informe de Posicionamiento Terap\u00e9utico de Onasemnogene abeparvovec (Zolgensma\u00ae) en Atrofia muscular espinal [Therapeutic Positioning Report of onasemnogene abeparvovec (Zolgensma\u00ae) in Spinal Muscular Atrophy]. [Website in Spanish]. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios, February 1, 2022. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2022\/IPT_11-2022-Zolgensma.pdf?x23738. Accessed 18 June 2026."},{"key":"1032_CR41","unstructured":"Ministerio de Sanidad, Servicos Sociales e Igualdad [Ministry of Health, Social Services and Equality]. Informe de Posicionamiento Terap\u00e9utico de risdiplam (Evrysdi\u00ae) en atrofia muscular espinal [Therapeutic Positioning Report of risdiplam (Evrysdi\u00ae) in Spinal Muscular Atrophy]. [Website in Spanish]. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios, March 7, 2022. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2022\/IPT_21-2022-Evrysdi.pdf?x42382. Accessed 18 June 2026."},{"key":"1032_CR42","unstructured":"Garc\u00eda P\u00e9rez L, Guirado Fuentes C, Vel\u00e1zquez Perell\u00f3 C, Valc\u00e1rcel Nazco C, Herrera Ramos E, Caza\u00f1a P\u00e9rez V. Coste-efectividad del cribado neonatal de la atrofia muscular espinal y la inmunodeficiencia combinada grave [Cost-effectiveness of neonatal screening for spinal muscular atrophy and severe combined immunodeficiency]. [Webpage in Spanish]. Ministerio de Sanidad. Servicio de Evaluaci\u00f3n del Servicio Canario de la Salud; 2024. Informes de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias. https:\/\/sescs.es\/wp-content\/uploads\/2015\/09\/SESCS_2022_COSTE_EFECTIVIDAD_CN_AME_IDCG.pdf. Accessed 18 June 2026."},{"issue":"4","key":"1032_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.46531\/sinapse\/AO\/210058\/2021","volume":"21","author":"J Costa","year":"2021","unstructured":"Costa J, Coelho T, Moreno T, et al. Burden of disease and cost of illness of spinal muscular atrophy in Portugal. Sinapse. 2021;21(4):212\u20139.","journal-title":"Sinapse"},{"issue":"4","key":"1032_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JND-190428","volume":"6","author":"K Vill","year":"2019","unstructured":"Vill K, K\u00f6lbel H, Schwartz O, et al. One year of newborn screening for SMA\u2014results of a German pilot project. J Neuromuscul Dis. 2019;6(4):503\u201315.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"1032_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","volume":"125","author":"L Al\u00edas","year":"2009","unstructured":"Al\u00edas L, Bernal S, Fuentes-Prior P, et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet. 2009;125(1):29\u201339.","journal-title":"Hum Genet"},{"key":"1032_CR46","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"C Darryl","year":"2019","unstructured":"Darryl C, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842\u201356.","journal-title":"Neuromuscul Disord"},{"key":"1032_CR47","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28:1390\u20137.","journal-title":"Nat Med"},{"key":"1032_CR48","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28:1381\u20139.","journal-title":"Nat Med"},{"key":"1032_CR49","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.4281","volume":"96","author":"RS Finkel","year":"2021","unstructured":"Finkel RS, Al-Muhaizea M, Farrar MA, et al. RAINBOWFISH: a study of Risdiplam in newborns with presymptomatic spinal muscular atrophy (SMA)(4281). Neurology. 2021;96:4281.","journal-title":"Neurology"},{"key":"1032_CR50","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"1032_CR51","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1212\/WNL.94.15_supplement.1640","volume":"94","author":"D Castro","year":"2020","unstructured":"Castro D, Finkel RS, Farrar MA, et al. Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study (1640). Neurology. 2020;94:1640.","journal-title":"Neurology"},{"key":"1032_CR52","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832\u201341.","journal-title":"Lancet Neurol"},{"key":"1032_CR53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al\u2010Zaidy","year":"2019","unstructured":"Al\u2010Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS\u2010101 gene replacement therapy. Pediatr Pulmonol. 2019;54:179\u201385.","journal-title":"Pediatr Pulmonol"},{"key":"1032_CR54","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284\u201393.","journal-title":"Lancet Neurol"},{"key":"1032_CR55","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82:883\u201391.","journal-title":"Ann Neurol"},{"key":"1032_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146:67\u201372.","journal-title":"J Neurol Sci"},{"key":"1032_CR57","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology. 2019;92:e2492\u2013506.","journal-title":"Neurology"},{"key":"1032_CR58","unstructured":"European Medicines Agency (EMA). Spinraza. EMA, August 4, 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza. Accessed 3 Sept 2026."},{"key":"1032_CR59","unstructured":"European Medicines Agency (EMA). Evrysdi. EMA, April 21, 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi. Accessed 3 Sept 2026."},{"key":"1032_CR60","unstructured":"European Medicines Agency (EMA). Zolgensma. EMA, August 20, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma. Accessed 3 Sept 2026."},{"key":"1032_CR61","unstructured":"SMA Europe. SMA Medicines Landscape. SMA Europe, 2025. https:\/\/www.sma-europe.eu\/sma-medicines-landscape. Accessed 2 June 2026."},{"key":"1032_CR62","doi-asserted-by":"publisher","first-page":"1889841","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, et al. An updated cost\u2013utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021;9:1889841.","journal-title":"J Mark Access Health Policy"},{"key":"1032_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12962-020-00234-8","volume":"18","author":"P Thokala","year":"2020","unstructured":"Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG, Chapman RH. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020;18:1\u201312.","journal-title":"Cost Eff Resour Alloc"},{"key":"1032_CR64","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131:e1509\u201314.","journal-title":"Pediatrics"},{"key":"1032_CR65","unstructured":"Gisbert R, Brosa M. Spanish health costs and cost-effectiveness ratios database: eSalud. Barcelona: Oblikue Consulting, S.L. 2007. http:\/\/www.oblikue.com\/bddcostes\/. Accessed 20 Nov 2025."},{"key":"1032_CR66","unstructured":"\u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf \u03a5\u03b3\u03b5\u03af\u03b1\u03c2 [Ministry of Health]. \u039f\u03c1\u03b8\u03ae \u0395\u03c0\u03b1\u03bd\u03ac\u03bb\u03b7\u03c8\u03b7 \u03c4\u03b7\u03c2 \u03943(\u03b1) 5623\/31.1.2024 \u00ab\u03a4\u03c1\u03bf\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03943(\u03b1) 67328\/29.12.2023 \u03b1\u03c0\u03cc\u03c6\u03b1\u03c3\u03b7\u03c2 \u03bc\u03b5 \u03b8\u03ad\u03bc\u03b1 \u00ab\u0394\u03b5\u03bb\u03c4\u03af\u03bf \u03b1\u03bd\u03b1\u03b8\u03b5\u03c9\u03c1\u03b7\u03bc\u03ad\u03bd\u03c9\u03bd \u03c4\u03b9\u03bc\u03ce\u03bd \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd, \u0394\u03b5\u03ba\u03b5\u03bc\u03b2\u03c1\u03af\u03bf\u03c5 2023\u00bb\u00bb, \u03c9\u03c2 \u03c0\u03c1\u03bf\u03c2 \u03c4\u03b1 Barcode \u0395\u039f\u03a6: 2803305601013, 2801897906141, 2803351402039, 2803351401032, 2803280602012 [Correct Repetition of D3(a) 5623\/31.1.2024 \"Amendment of D3(a) 67328\/29.12.2023 decision on the subject of \"Bulletin of revised drug prices, December 2023\"\", regarding the EOF Barcodes: 2803305601013, 2801897906141, 2803351402039, 2803351401032, 2803280602012] [Website in Greek]. \u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf \u03a5\u03b3\u03b5\u03af\u03b1\u03c2, February 9, 2024. https:\/\/www.moh.gov.gr\/articles\/times-farmakwn\/deltia-timwn\/12180-orthh-epanalhpsh-ths-d3-a-5623-31-1-2024-laquo-tropopoihsh-ths-ypo-stoixeia-d3-a-67328-29-12-2023-laquo-deltio-anathewrhmenwn-timwn-farmakwn-dekembrioy-2023-raquo-raquo-ws-pros-ta-barcode-eof-2803305601013-2801897906141-2803351402039-2803351401032-2803280. Accessed 20 Nov 2025."},{"key":"1032_CR67","unstructured":"Infarmed Autoridade Nacional do Medicamento e Produtos de Sa\u00fade I.P. Availability of medicines. Infarmed, 2021. https:\/\/www.infarmed.pt\/web\/infarmed-en\/availability-of-medicines. Accessed 20 Nov 2025."},{"key":"1032_CR68","unstructured":"Red Espa\u00f1ola de Costes Hospitalarios (rech). Introducci\u00f3n [Introduction][Website in Spanish]. Grupo RECH; 2025. https:\/\/www.rechosp.org\/faces\/es\/jsf\/empezar.jsp. Accessed 20 Nov 2025."},{"key":"1032_CR69","unstructured":"Greek Ministry of Health. List of Diagnosis Related Groups. Government Gazette \u03a6\u0395\u039a 2150_27 \u03a3\u03b5\u03c0\u03c4\u03b5\u03bc\u03b2\u03c1\u03af\u03bf\u03c5 2011. [Website in Greek]. Greek Ministry of Health; 2025. https:\/\/www.ippokratio.gr\/wp-content\/uploads\/%CE%A6%CE%95%CE%9A-2150-%CE%92-2011-%CE%9A%CE%95%CE%9D.pdf. Accessed 28 Jan 2026."},{"key":"1032_CR70","unstructured":"Greek Ministry of Health. Updated List of Diagnosis Related Groups from 1\/3\/2012. Government Gazette \u03a6\u0395\u039a 946_27 \u039c\u03b1\u03c1\u03c4\u03af\u03bf\u03c5 2012 [Website in Greek]. Greek Ministry of Health; 2025. https:\/\/www.moh.gov.gr\/articles\/health\/domes-kai-draseis-gia-thn-ygeia\/kwdikopoihseis\/kleista-enopoihmena-noshlia\/1079-nea-lista-ken-apo-1-3-2012-kostos-mdn. Accessed 28 Jan 2026."},{"key":"1032_CR71","unstructured":"Ministry of Health. [List of medicines affected by the deductions of Royal Decree-Law 8\/2010\u2014March 2025]. 2025. https:\/\/www.sanidad.gob.es\/areas\/farmacia\/infoIndustria\/infoDeducciones\/ley8_2010\/docs\/Deducciones_MARZO_2025.pdf. Accessed 4 Feb 2026."},{"key":"1032_CR72","unstructured":"Castilla I, Vallejo-Torres L, Couce ML, et al. Cost-effectiveness of newborn screening for primary carnitine deficiency. Servicio Canario de la Salud, Gobierno de Canarias; May 6, 2015. https:\/\/www3.gobiernodecanarias.org\/sanidad\/scs\/contenidoGenerico.jsp?idDocument=ea1a6177-03a6-11e5-9e16-d107cd1682ec&idCarpeta=ae273cd1-b385-11e9-82f7-8d5cff9227e6. Accessed 20 Nov 2025."},{"key":"1032_CR73","unstructured":"National Institute for Public Health and the Environment. 2020. RIVM Portaria n.\u00ba 254\/2018 Codes 34655 and 34656. [Website in Portuguese]. https:\/\/diariodarepublica.pt\/dr\/detalhe\/portaria\/254-2018-116353279. Accessed 26 Nov 2025."},{"key":"1032_CR74","unstructured":"General Council of the Official College of Pharmacists. Farmacy Portal. BotPlus [Website in Spanish]. https:\/\/botplusweb.portalfarma.com\/botplus.aspx. Accessed 20 Nov 2025."},{"key":"1032_CR75","unstructured":"IMPIC Base: Contratos P\u00fablicos Online. Bem-vindo. O Portal BASE centraliza a informa\u00e7\u00e3o sobre os contratos p\u00fablicos celebrados em Portugal continental e regi\u00f5es aut\u00f3nomas [The BASE Portal centralizes information on public contracts concluded in mainland Portugal and autonomous regions] [Website in Portuguese]. Portal BASE\u2014Online Public Contracts, October 6, 2025. https:\/\/www.base.gov.pt\/base4. Accessed 20 Nov 2025."},{"key":"1032_CR76","unstructured":"Novartis. Novartis Gene Therapies. Novartis, 2025. https:\/\/www.novartis.com\/about\/novartis-gene-therapies. Accessed 20 Nov 2025."},{"key":"1032_CR77","unstructured":"Di\u00e1rio da Rep\u00fablica, 1.\u00aa S\u00e9rie. Portaria n.\u00ba 254\/2018\u2014Codes 63610, 32525, 32050, 10545, September 7, 2018. [Website in Portuguese]. https:\/\/static.sanchoeassociados.com\/DireitoMedicina\/Omlegissum\/legislacao2018\/Setembro\/Port_254_2018.pdf. Accessed 4 Feb 2026."},{"key":"1032_CR78","unstructured":"National Institute for Health and Care Excellence (NICE). Onasemnogene abeparvovec for treating spinal muscular atrophy. Highly specialised technologies guidance. HST15. NICE, July 7, 2021. https:\/\/www.nice.org.uk\/guidance\/hst15. Accessed 20 Nov 2025."},{"key":"1032_CR79","doi-asserted-by":"publisher","first-page":"A725","DOI":"10.1016\/j.jval.2017.08.1962","volume":"20","author":"R Thompson","year":"2017","unstructured":"Thompson R, Vaidya S, Teynor M. The utility of different approachs to developing health utilities data in childhood rare diseases\u2014a case study in spinal muscular atrophy (SMA). Value Health. 2017;20:A725\u20136.","journal-title":"Value Health"},{"key":"1032_CR80","volume-title":"Nusinersen for treating spinal muscular atrophy: a single technology appraisal","author":"P Tappenden","year":"2018","unstructured":"Tappenden P, Hamilton J, Kaltenthaler E, et al. Nusinersen for treating spinal muscular atrophy: a single technology appraisal. Berlin: School of Health and Related Research (ScHARR); 2018."},{"key":"1032_CR81","unstructured":"Institute for Clinical and Economic Review (ICER). Spinraza and Zolgensma for spinal muscular atrophy: effectiveness and value. Final Evidence Report. ICER, April 3, 2019; updated May 24, 2019. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_110220.pdf. Accessed 4 Feb 2026."},{"key":"1032_CR82","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/j.nmd.2020.08.273","volume":"30","author":"L Servais","year":"2020","unstructured":"Servais L, Bertini E, Al-Muhaizea M, et al. SMA-THERAPY: P 274 RAINBOWFISH: a study of risdiplam (RG7916) in infants with presymptomatic spinal muscular atrophy (SMA). Neuromuscul Disord. 2020;30:S127.","journal-title":"Neuromuscul Disord"},{"key":"1032_CR83","unstructured":"Heijnen ML, Jansen M, van Gorp AGM, Hillen D, Elsinghorst E, Klein A. Uitvoeringstoets toevoeging Spinale Musculaire Atrofie aan de neonatale hielprikscreening [Implementation test for the addition of Spinal Muscular Atrophy to the neonatal heel prick screening] [Website in Dutch]. Rijksinstituut voor Volksgezondheid en Milieu, September 30, 2020. https:\/\/www.rivm.nl\/publicaties\/uitvoeringstoets-toevoeging-sma-aan-hielprik. Accessed 20 Nov 2025."},{"key":"1032_CR84","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.1429","volume":"94","author":"NB Johnson","year":"2020","unstructured":"Johnson NB, Paradis AD, Naoshy S, Wong J, Montes J, Krasinski DC. Evaluation of nusinersen on impact of caregiver experience and HRQOL in later-onset spinal muscular atrophy (SMA): results from the phase 3 CHERISH trial (1429). Neurology. 2020;94:1429.","journal-title":"Neurology"},{"key":"1032_CR85","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/CEOR.S214084","volume":"11","author":"AJ Lloyd","year":"2019","unstructured":"Lloyd AJ, Thompson R, Gallop K, Teynor M. Estimation of the quality of life benefits associated with treatment for spinal muscular atrophy. Clinicoecon Outcomes Res.\u00a02019;11:615\u201322.\u00a0https:\/\/doi.org\/10.2147\/CEOR.S214084.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"1032_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ijns10030056","volume":"10","author":"K Cooper","year":"2024","unstructured":"Cooper K, Nalbant G, Sutton A, et al. Systematic review of presymptomatic treatment for spinal muscular atrophy. Int J Neonatal Screen. 2024;10(3):56. https:\/\/doi.org\/10.3390\/ijns10030056.","journal-title":"Int J Neonatal Screen"},{"issue":"5","key":"1032_CR87","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","volume":"31","author":"N Gusset","year":"2021","unstructured":"Gusset N, Stalens C, Stumpe E, et al. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Neuromuscul Disord. 2021;31(5):419\u201330. https:\/\/doi.org\/10.1016\/j.nmd.2021.01.012.","journal-title":"Neuromuscul Disord"},{"key":"1032_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1214766","volume":"11","author":"R Raycheva","year":"2023","unstructured":"Raycheva R, Kostadinov K, Mitova E, et al. Challenges in mapping European rare disease databases, relevant for ML-based screening technologies in terms of organizational, FAIR and legal principles: scoping review. Front Public Health. 2023;11:1214766. https:\/\/doi.org\/10.3389\/fpubh.2023.1214766.","journal-title":"Front Public Health"},{"issue":"9","key":"1032_CR89","doi-asserted-by":"publisher","first-page":"P563","DOI":"10.1097\/01.gim.0000237790.54074.3d","volume":"8","author":"T Hoff","year":"2006","unstructured":"Hoff T, Hoyt A, Therrell B, Ayoob M. Exploring barriers to long-term follow-up in newborn screening programs. Genet Med. 2006;8(9):P563\u201370. https:\/\/doi.org\/10.1097\/01.gim.0000237790.54074.3d.","journal-title":"Genet Med"},{"issue":"3","key":"1032_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijns9030035","volume":"9","author":"B Odenwald","year":"2023","unstructured":"Odenwald B, Brockow I, Hanauer M, L\u00fcders A, Nennstiel U. Is our newborn screening working well? A literature review of quality requirements for newborn blood spot screening (NBS) infrastructure and procedures. Int J Neonatal Screen. 2023;9(3):35. https:\/\/doi.org\/10.3390\/ijns9030035.","journal-title":"Int J Neonatal Screen"},{"issue":"3","key":"1032_CR91","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40273-022-01197-9","volume":"41","author":"E Landfeldt","year":"2023","unstructured":"Landfeldt E, Abner S, Pechmann A, et al. Caregiver burden of spinal muscular atrophy: a systematic review. Pharmacoeconomics. 2023;41(3):275\u201393. https:\/\/doi.org\/10.1007\/s40273-022-01197-9.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR92","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78:834\u201341.","journal-title":"JAMA Neurol"},{"key":"1032_CR93","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.2301","volume":"96","author":"J Mendell","year":"2021","unstructured":"Mendell J, Finkel R, Mercuri E, et al. Long-term follow-up (LTFU) of onasemnogene abeparvovec gene therapy in spinal muscular atrophy (SMA) (2301). Neurology. 2021;96:2301.","journal-title":"Neurology"},{"issue":"2","key":"1032_CR94","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JND-190468","volume":"7","author":"J Glascock","year":"2020","unstructured":"Glascock J, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening. J Neuromuscul Dis. 2020;7(2):97\u2013100.","journal-title":"J Neuromuscul Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01032-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01032-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01032-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:02:13Z","timestamp":1790002933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01032-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":94,"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01032-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Raquel Yahyaoui received a grant from Novartis to co-fund a pilot program for neonatal SMA screening in Eastern Andalusia in 2022\u20132023, and also received remuneration for participation in the 2022 data collection for this analysis. Argirios Dinopoulos received honoraria, travel, and research grants from Biogen, Roche, and Novartis. Francina Munell served as a consultant, scientific advisory board member, and site principal investigator for trials sponsored by Novartis, Roche, and Biogen, and also received remuneration for participation in the 2022 data collection for this analysis. Jos\u00e9 Pedro Vieira received honoraria from Novartis, Roche, and Biogen for participation in advisory boards and from Novartis as a speaker. Manuela A. Santos reports no conflicts of interest regarding this publication. David G\u00f3mez-Andr\u00e9s has no conflicts to disclose. Grace McCarthy is an employee of Novartis and owns stock\/other equities. Matthias Bischof is an employee of Novartis and owns stock\/other equities. Michel\u00a0A. Kroes is an employee of Novartis and owns stock\/other equities. Dimitrios I. Zafeiriou received honoraria, travel, and research grants from Biogen, Roche, and Novartis. Francina Munell and David G\u00f3mez-Andr\u00e9s are members of the European Reference Network for Neuromuscular Diseases\u2014Project ID n\u00b0101156434.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on a cost-utility analysis using a combination of decision tree and Markov model structures. No new studies with human participants were included in this analysis, and, therefore, Institutional Review Board approval was not required, patient consent to participate was not necessary, and the Declaration of Helsinki 1964 does not apply.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}